<DOC>
	<DOCNO>NCT01034345</DOCNO>
	<brief_summary>In contrast calcineurin inhibitor , sirolimus know exert remarkable tolerance-promoting property multiple animal transplant model . Whether sirolimus capable enhance tolerance-related pathway and/or promote complete withdrawal immunosuppressive drug human transplant recipient previously address . The goal investigator study evaluate effect sirolimus previously identify tolerogenic pathway human , indirectly , assess capacity drug enhance proportion liver recipient undergo successful immunosuppression weaning .</brief_summary>
	<brief_title>Effect Rapamycin Tolerance-related Biomarkers Stable Liver Transplant Recipients</brief_title>
	<detailed_description>Objective : To test liver transplant recipient identify non-tolerant whether discontinuation calcineurin inhibitor follow 6-month treatment sirolimus modifies pattern expression set gene associate tolerance Background : Sirolimus immunosuppressive drug use counter autoimmunity prevent acute graft rejection human remarkable tolerance-promoting property animal transplant model . Hypothesis/Specific Aims : We hypothesize sirolimus promotes tolerogenic pathway human liver transplantation . 1 . To test liver transplant recipient identify non-tolerant whether discontinuation calcineurin inhibitor follow 6-month treatment sirolimus modifies pattern expression set gene associate tolerance 2 . To test liver transplant recipient identify non-tolerant whether conversion calcineurin inhibitor sirolimus modifies memory type immune response . 3 . To test liver transplant recipient identify non-tolerant whether conversion calcineurin inhibitor monotherapy sirolimus affect frequency , phenotype function potentially immunoregulatory peripheral blood lymphocyte subsets 4 . To test liver transplant recipient identify non-tolerant whether conversion calcineurin inhibitor sirolimus promote epigenetic change relate immunoregulation cancer development/progression Proposed Methods : Gene expression experiment : quantify expression peripheral blood set gene previously identify predictive successful immunosuppression withdrawal stable liver transplant recipient . Blood sample obtain 6 month conversion sirolimus treatment . Measurement gene expression level conduct employ real-time TaqMan PCR . Classification patient tolerant/non-tolerant category conduct utilizing threshold predictive algorithm develop laboratory . Immunophenotyping study : quantify peripheral blood various mononuclear cell subset implicate immunoregulatory pathway 6 month conversion sirolimus treatment . Measurements conduct employ flow cytometry . Functional assay : isolate CD4+CD25+ regulatory T cell ( Treg ) peripheral blood Sorter 6 month conversion sirolimus treatment . Serial dilution experiment conduct antigen non-specific assay ass relative suppressive property Tregs . IFNg ELISpot assay conduct parallel employ peripheral blood mononuclear cell responder cell measure donor-specific alloimmune response . Measurement DNA-methylation : recipient DNA extract peripheral blood sample 6-month sirolimus treatment use conduct whole-genome methylation study employ ILLUMINA array platform . Expected result : We expect precisely define effect sirolimus previously identify tolerogenic pathway human , assess capacity drug enhance proportion liver recipient undergo successful immunosuppression weaning .</detailed_description>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age ≥ 18 year weight ≥ 40 kg Women childbearing potential must negative serum pregnancy test result random assignment must agree use medically acceptable method contraception throughout treatment period 3 month discontinuation randomly assign treatment . Any woman become pregnant treatment period must withdraw study Subjects receive immunosuppressive therapy stable regimen calcineurin inhibitor combination calcineurin inhibitor corticosteroid and/or antimetabolite therapy minimum 4 week prior randomization Recipient liver transplantation &gt; 3 year followup CockcroftGault GFR value ≥ 40 mL/min Total white blood cell count &gt; 3.0 x 109/L ( &gt; 3,000/mm3 ) , platelet count &gt; 75 x109/L ( &gt; 75,000/mm3 ) , fast triglyceride &lt; 3.95 mmol/L ( &lt; 350 mg/dL ) , fast cholesterol &lt; 7.8 mmol/L ( &lt; 300 mg/dL ) . If subject currently untreated elevate cholesterol and/or triglyceride exclude study base criterion , subject offer antihyperlipidemic therapy . Stable liver function define : ) normal liver function test ( AST , ALT , ALP , GGT ) previous 6 month ; alternatively b ) minor alteration liver function test change previous 6 month ( AST/ALT &lt; 2 fold normal level ; ALP &lt; 1.5 fold normal level ; GGT &lt; 3 fold normal level ; bilirubin &lt; 3 mg/dL ) . Absence treatment interferon hepatitis C virus infection Absence autoimmune disease require immunosuppressive therapy Absence autoimmune liver disease indication transplantation Absence rejection episodes 12 previous month Peripheral blood gene expression profile characteristic nontolerant recipient ( likelihood successful wean &lt; 5 % ) Written , sign , date IRB IECapproved inform consent Requirement treatment immunosuppressive drug indication prevention rejection Proteinuria level &gt; 0.8 g/day Evidence systemic infection ( e , g. , sepsis , bacteremia , pneumonia , etc . ) time random assignment . History document human immunodeficiency virus infection . Hypercoagulable state history deep vein thrombosis , HAT , portal vein thrombosis . ( Exception : incidental vascular thrombosis time liver explant , opinion investigator , place subject increase risk thrombotic event . ) Transplant graft addition liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Tolerance</keyword>
	<keyword>Immune response</keyword>
	<keyword>Allograft tolerance</keyword>
</DOC>